| Patent application number | Description | Published |
|---|
| 20080206754 | Method for producing monoclonal antibodies - An improved method for the production of monoclonal antibodies is disclosed. | 08-28-2008 |
| 20080213253 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a vascular disrupting agent. | 09-04-2008 |
| 20080241127 | Methods of Making Passive Immunotherapies - Methods for isolating antibodies useful as passive immunotherapies are described. | 10-02-2008 |
| 20080274490 | PD-1, a receptor for B7-4, and uses therefor - Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on an immune cell. The method comprises contacting an antigen presenting cell which expresses B7-4 with an agent such as a form of B7-4, a form of PD-1, or an agent that modulates the interaction of B7-4 and PD-1. Also disclosed is a method for inhibiting activation of an immune cell via a non-apoptotic mechanism by increasing the activity or expression of PD-1 in the immune cell. The disclosed methods for modulating an immune response are useful, for instance as therapeutic treatment of a subject with conditions that would benefit from immune response modulation. For instance, a condition such as a tumor, a neurological disease, or an immunosuppressive disease, would be treated by upregulating an immune response, and conditions such as a transplant, an allergy, or an autoimmune disorder would benefit from downregulation of an immune response. Assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule are also disclosed. Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1. | 11-06-2008 |
| 20080311117 | Antibodies against PD-1 and uses therefor - This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders. | 12-18-2008 |
| 20090186031 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS - Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis. | 07-23-2009 |
| 20090203060 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 08-13-2009 |
| 20090214520 | Soluble CLCA-1 and antagonists to CLCA-1 - The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid. | 08-27-2009 |
| 20100028330 | METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES - This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders. | 02-04-2010 |
| 20100196361 | Method of inhibition of vascular development using an antibody - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders. | 08-05-2010 |
| 20100266490 | Metalloproteinase Binding Proteins - Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. | 10-21-2010 |
